ArticleMolecular therapy. Oncology2025
Tackling cancer heterogeneity with systemically delivered oncolytic adenoviruses transcriptionally targeted with hybrid promoters.
Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor escape driven by cancer heterogeneity is a hallmark of human malignancies. Oncolytic adenoviruses (OAds) are transcriptionally targeted to selectively replicate in cancer cells through the use of tumor-specific promoters (TSPs). The aim of our study was to establish whether we can tackle cancer heterogeneity with OAds transcriptionally targeted with hybrid TSPs (hTSPs). Following a comprehensive bioinformatic and molecular screening process, we identified the A33 and vWA2 promoters (Prs) as optimal candidates to combine them to construct an hTSP to drive the replication of a novel OAd named AR2015. To validate its efficacy, we evaluated AR2015 in various human colorectal cancer (CRC) cell lines, patient-derived cells, and nude mouse models and compared it with two OAds driven by single TSPs (either A33-Pr or vWA2-Pr). AR2015 exhibited efficient replication in both A33-positive and vWA2-positive CRC cell lines, effectively broadening the oncolytic spectrum and overcoming the limitations of single-Pr OAds. Systemic administration of AR2015 significantly inhibited the growth of CRC-derived liver metastases expressing A33 and vWA2, with further therapeutic benefit observed in combination with oxaliplatin. These findings provide proof of concept for addressing tumor heterogeneity through transcriptionally targeted OAds driven by hTSPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.